NCT05176509View on ClinicalTrials.gov

A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 5, 2022

Primary Completion Date

August 23, 2023

Study Completion Date

August 25, 2023

Conditions
Solid Tumor
Interventions
DRUG

YH003

YH003 will be administered intravenously over 60 minutes every 21-day cycle.

DRUG

YH001

YH001 will be administered intravenously over 60 minutes every 21-day cycle.

DRUG

Pembrolizumab

Pembrolizumab will be administered intravenously over 30 minutes every 21-day cycle.

Trial Locations (4)

2148

Blacktown Cancer and Haematology Centre, Clinical Trials, Block C, Level 3, 18 Blacktown Road, Blacktown

2217

"Oncology Clinical Trial Unit St George Private Hospital 1 South Street", Kogarah

Unknown

55 Commercial Rd, Level 2 WBRC, Melbourne

Level 3, Suite 7, North Building, Frankston Private, 5 Susono Way, Frankston, Prahran

All Listed Sponsors
lead

Eucure (Beijing) Biopharma Co., Ltd

INDUSTRY